Can B (CANB) 10-K 2 Apr 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 13, 2020	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Can B Corp
Entity Central Index Key	0001509957
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 4,466,469
Entity Common Stock, Shares Outstanding		2,861,740
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 46,540	$ 807,747
Accounts receivable, less allowance for doubtful accounts of $0 and $0, respectively	1,251,609	39,172
Inventory	784,497	87,104
Note Receivable	24,268
Prepaid expenses - current	1,279,901	210,351
Total current assets	3,386,815	1,144,374
Property and equipment, at cost less accumulated depreciation of $116,555 and $20,248, respectively	1,075,242	59,619
Other assets:
Deposit - noncurrent	21,287	48,726
Prepaid expenses - noncurrent	1,179,929	2,365,719
Note receivable - noncurrent		19,389
Other receivable - noncurrent	58,206
Intangible assets, net of accumulated amortization of $202,521 and $0, respectively	1,056,562
Goodwill	55,849	55,849
Right-of-Use Asset, net of amortization of $6,280 and $0, respectively	96,980
Total other assets	2,468,813	2,489,683
Total assets	6,930,870	3,693,675
Current liabilities:
Accounts payable	226,467	73,059
Accrued officers' compensation	144,363	68,750
Other accrued expenses payable	61,557	43,778
Notes and loans payable	35,000	19,205
Current portion of lease liability	38,281
Total current liabilities	505,668	204,792
Non-current portion of lease liability	58,998
Total liabilities	564,666	204,792
Commitments and contingencies (Notes 14)
Stockholders' equity:
Common stock, no par value; authorized 1,500,000,000 shares, issued and outstanding 804,281,149 and 440,566,325 shares, respectively	23,113,077	16,624,557
Additional Paid-in capital	872,976	872,976
Additional Paid-in capital - Stock Options (Note 11)	202,200	202,200
Accumulated deficit	(23,361,223)	(18,768,753)
Total stockholders' equity	6,366,204	3,488,883
Total liabilities and stockholders' equity	6,930,870	3,693,675
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock, authorized 5,000,000 shares:	5,539,174	4,557,424
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred stock, authorized 5,000,000 shares:		$ 479

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 0	$ 0
Accumulated depreciation, property and equipment	116,555	20,248
Amortization of intangible assets	202,521	0
Depreciation of Right-of-use Asset	$ 6,280	$ 0
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value
Common stock, shares authorized	1,500,000,000	1,500,000,000
Common stock, shares issued	804,281,149	440,566,325
Common stock, shares outstanding	804,281,149	440,566,325
Series A Preferred Stock [Member]
Preferred stock, shares authorized	20	20
Preferred stock, par value
Preferred stock, shares issued	20	18
Preferred stock, shares outstanding	20	18
Series B Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	0	499,958
Preferred stock, shares outstanding	0	499,958

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues
Total Revenues	$ 2,305,503	$ 668,603
Cost of product sales	598,584	405,534
Gross Profit	1,706,919	263,069
Operating costs and expenses:
Officers and director's compensation (including stock-based Compensation of $1,210,915 and $1,255,193, respectively)	2,263,566	1,478,987
Consulting fees (including stock-based compensation of 1,858,837 and 1,524,107, respectively)	2,082,184	1,669,443
Advertising expense	333,441	84,316
Hosting expense	13,034	14,697
Rent expense	246,968	67,165
Professional fees	287,441	117,718
Depreciation of property and equipment	12,627	5,473
Amortization of intangible assets	142,093
Reimbursed Expenses	242,585
Other	667,097	241,044
Total operating expenses	6,291,036	3,678,843
Loss from operations	(4,584,117)	(3,415,774)
Other income (expense):
Loss on forgiveness of receivable from Pure Health Products		(85,827)
Loss of debt conversions		(1,299,369)
Loss on stock issuance		(649,259)
Interest income	2,524	10,325
Income from derivative liability		1,591,137
Interest expense (including amortization of debt discounts of $0 and 176,497, respectively)	(8,793)	(263,510)
Other income (expense) - net	(6,269)	(696,503)
Loss before provision for income taxes	(4,590,386)	(4,112,277)
Provision for income taxes	2,084
Loss and comprehensive loss	$ (4,592,470)	$ (4,112,277)
Net loss per common share - basic and diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - Basic	617,557,484	276,026,704
Weighted average common shares outstanding - Diluted	806,215,018	423,881,781
Product [Member]
Revenues
Total Revenues	$ 2,304,303	$ 651,978
Service [Member]
Revenues
Total Revenues	$ 1,200	$ 16,625

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock-based compensation	$ 3,089,188	$ 2,779,300
Amortization of debt discounts		176,497
Consulting Fees [Member]
Stock-based compensation	1,858,837	1,524,107
Officers and Directors [Member]
Stock-based compensation	$ 1,210,915	$ 1,255,193

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock A [Member]
Balance	$ 4,557,424	$ 243,537
Balance, shares	18	8
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement		$ 4,441,690
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement, shares		13
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement	$ 992,250
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement, shares	3
Issuance of common stock for retirement of Series A preferred stock	$ (10,500)	$ (127,803)
Issuance of common stock for retirement of Series A preferred stock, shares	(1)	(3)
Issuance of common stock for retirement of Series B preferred stock In 2018
Issuance of common stock for retirement of Series B preferred stock In 2018, shares
Net loss
Balance	$ 5,539,174	$ 4,557,424
Balance, shares	20	18
Preferred Stock B [Member]
Balance	$ 479	$ 150
Balance, shares	499,958	157,985
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement
Sale of Series B Preferred Stock in 2018		$ 749
Sale of Series B Preferred Stock in 2018, shares		761,972
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement
Issuance of common stock for retirement of Series A preferred stock
Issuance of common stock for retirement of Series B preferred stock In 2018	$ (479)	$ (420)
Issuance of common stock for retirement of Series B preferred stock In 2018, shares	(499,958)	(419,999)
Net loss
Balance		$ 479
Balance, shares		499,958
Common Stock [Member]
Balance	$ 16,624,557	$ 12,524,042
Balance, shares	440,566,325	225,572,323
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement
Issuance of common stock in 2018 for services rendered		$ 656,306
Issuance of common stock in 2018 for services rendered, shares		19,345,789
Issuance of common stock in 2018 for Preferred B dividends		$ 38,379
Issuance of common stock in 2018 for Preferred B dividends, shares		891,089
Issuance of common stock in 2018 in Satisfaction of debt and accrued interest		$ 1,604,412
Issuance of common stock in 2018 in Satisfaction of debt and accrued interest, shares		45,263,513
Issuance of common stock in 2018 for Warrant exercise		$ 619,880
Issuance of common stock in 2018 for Warrant exercise, shares		8,500,000
Issuance of common stock in 2018 in Satisfaction of accrued compensation		$ 192,300
Issuance of common stock in 2018 in Satisfaction of accrued compensation, shares		4,370,629
Issuance of common stock in 2018 for Acquisition of PureHealth, LLC		$ 112,415
Issuance of common stock in 2018 for Acquisition of PureHealth, LLC, shares		3,096,827
Issuance of stock options for retirement Of common shares		$ (101,400)
Issuance of stock options for retirement Of common shares, shares		(3,000,000)
Sale of common stocks	$ 3,296,700	$ 850,000
Sale of common stocks, shares	113,866,481	29,821,201
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement
Issuance of common stock for retirement of Series A preferred stock	$ 10,500	$ 127,803
Issuance of common stock for retirement of Series A preferred stock, shares	10,000,000	30,000,000
Issuance of common stock for retirement of Series B preferred stock In 2018	$ 479	$ 420
Issuance of common stock for retirement of Series B preferred stock In 2018, shares	75,039,446	76,704,954
Issuance of common stock in 2019 for acquisition of technology and licenses	$ 648,655
Issuance of common stock in 2019 for acquisition of technology and licenses, shares	20,574,089
Issuance of common stock in 2019 for acquisition of inventory	$ 487,500
Issuance of common stock in 2019 for acquisition of inventory, shares	37,500,000
Issuance of common stock in 2019 for satisfaction of accrued salaries	$ 54,340
Issuance of common stock in 2019 for satisfaction of accrued salaries, shares	667,959
Issuance of common stock in 2019 for services rendered	$ 1,990,346
Issuance of common stock in 2019 for services rendered, shares	106,066,849
Net loss
Balance	$ 23,113,077	$ 16,624,557
Balance, shares	804,281,149	440,566,325
Additional Paid-in Capital [Member]
Balance	$ 1,075,176	$ 149,850
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement
Sale of Series B Preferred Stock in 2018		723,126
Issuance of stock options for retirement Of common shares		84,000
Issuance of stock options		118,200
Sale of common stocks
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement
Issuance of common stock for retirement of Series A preferred stock
Issuance of common stock for retirement of Series B preferred stock In 2018
Issuance of common stock in 2019 for acquisition of technology and licenses
Issuance of common stock in 2019 for acquisition of inventory
Issuance of common stock in 2019 for satisfaction of accrued salaries
Net loss
Balance	1,075,176	1,075,176
Accumulated Deficit [Member]
Balance	(18,768,753)	(14,647,476)
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement
Issuance of common stock in 2018 for Preferred B dividends		(9,000)
Sale of common stocks
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement
Issuance of common stock for retirement of Series A preferred stock
Issuance of common stock for retirement of Series B preferred stock In 2018
Issuance of common stock in 2019 for acquisition of technology and licenses
Issuance of common stock in 2019 for acquisition of inventory
Issuance of common stock in 2019 for satisfaction of accrued salaries
Net loss	(4,592,470)	(4,112,277)
Balance	(23,361,223)	(18,768,753)
Balance	3,488,883	(1,729,897)
Issuance of Series A Preferred Stock in 2018 pursuant to employment and consulting agreement		4,441,690
Sale of Series B Preferred Stock in 2018		723,875
Issuance of common stock in 2018 for services rendered		656,306
Issuance of common stock in 2018 for Preferred B dividends		29,379
Issuance of common stock in 2018 in Satisfaction of debt and accrued interest		1,604,412
Issuance of common stock in 2018 for Warrant exercise		619,880
Issuance of common stock in 2018 in Satisfaction of accrued compensation		192,300
Issuance of common stock in 2018 for Acquisition of PureHealth, LLC		112,415
Issuance of stock options for retirement Of common shares		(17,400)
Issuance of stock options		118,200
Sale of common stocks	3,296,700	850,000
Issuance of Series A Preferred Stock in 2019 pursuant to employment agreement	992,250
Issuance of common stock for retirement of Series A preferred stock
Issuance of common stock for retirement of Series B preferred stock In 2018
Issuance of common stock in 2019 for acquisition of technology and licenses	648,655
Issuance of common stock in 2019 for acquisition of inventory	487,500
Issuance of common stock in 2019 for satisfaction of accrued salaries	54,340
Issuance of common stock in 2019 for services rendered	1,990,346
Net loss	(4,592,470)	(4,112,277)
Balance	$ 6,366,204	$ 3,488,883

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Activities:
Net loss	$ (4,592,470)	$ (4,112,277)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation, net of prepaid stock- based consulting fees	3,089,188	2,779,300
Loss on forgiveness of receivable from PHP		85,827
Loss on stock issuance		649,259
Loss on debt conversion		1,299,369
Debt issuance expense		14,000
Expense from derivative liability		(1,591,137)
Depreciation of property and equipment	12,627	5,473
Amortization of intangible assets	142,093
Amortization of debt discounts		176,497
Bad debt expense	253,483
Changes in operating assets and liabilities:
Accounts receivable	(1,465,920)	(33,097)
Inventory	(209,893)	2,382
Prepaid expenses	(4,760)
Security deposit	27,439	(34,939)
Other receivable	(58,206)
Right-of-use asset	299
Accounts payable	153,408	(115,235)
Accrued officer's compensation	144,363	85,900
Other accrued expenses payable	17,777	35,109
Net cash used in operating activities	(2,413,420)	(753,569)
Investing Activities:
Cash received from acquisition of PHP		404
Note receivable - current	(4,879)
Fixed assets additions	(1,105,403)
Intangible assets additions	(550,000)	(46,384)
Net cash used in investing activities	(1,660,282)	(45,980)
Financing Activities:
Proceeds received from notes and loans payable	35,000	155,000
Repayments of notes and loans payable	(19,205)	(123,231)
Proceeds from sale of common stock	3,296,700	850,000
Proceeds from sale of Series B preferred stock		723,875
Net cash provided by financing activities	3,312,495	1,605,644
(Decrease)Increase in cash and cash equivalents	(761,207)	806,095
Cash and cash equivalents, beginning of period	807,747	1,652
Cash and cash equivalents, end of period	46,540	807,747
SUPPLEMENTAL CASH FLOW INFORMATION:
Income taxes paid	2,084
Interest paid	8,793
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock in acquisition of inventory	487,500
Issuance of common stock in acquisition of intangible assets	648,655
Amortization of prepaid issuance of common Stock for services rendered	121,000
Issuance of common stock in satisfaction of officer's compensation	68,750	282,200
Issuance of common stock in conversion of Series A Preferred Stock	10,500
Issuance of common stock in retirement of Series B Preferred Stock	479
Issuance of common stock in satisfaction of debt		262,000
Issuance of common stock in acquisition of PHP		178,997
Cancellation of note receivable and accrued interest in exchange for service		19,611
Cancellation of note receivable and accrued interest in acquisition of PHP		8,582,725
Issuance of common stock in satisfaction of accrued interest		$ 43,043

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	NOTE 1 – Organization and Description of Business Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April 2, 2008. The Company is in the process of dissolving Prosperity. The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company’s durable equipment products, such as sam® units with CBD infused pads, are marketed and sold through its wholly-owned newly formed subsidiaries, Duramed Inc. (incorporated in or around November 2018) and DuramedNJ LLC (incorporated in or around May 2019) (collectively, “Duramed”). Duramed began operating on or about February1, 2019. The Company’s wholly-owned subsidiary, Radical Tactical LLC (“Radical Tactical”), formed May, 2019 provides the marketplace with millennium targeted product lines such as vapes, gums, and kratom. The Company’s hemp aggregation business is run through NY Hemp Depot LLC (the “Hemp Depot”), which was formed in or around July, 2019. The Company’s hemp farming business is run through Green Grow Farms, Inc. (“Green Grow Farms”), which was formed in August, 2019. Effective December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1 for 10 reverse stock split of its common stock. The accompanying consolidated financial statements retroactively reflect these stock splits of March 6, 2020 for a 300:1 reverse split. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On March 6, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company” or “CANB” or “Can B” or “Registrant”). Can B̅ specializes in the production and sale of a variety of hemp derived Cannabidiol (“CBD”) products such as oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates. Can B̅ is developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the Hemp Industry. Can B̅ aims to be the premier provider of the highest quality hemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will improve people’s lives in a variety of areas. The Company also owns document management and email marketing platforms which it is seeking to sell or repurpose. For the periods presented, the assets, liabilities, revenues, and expenses are those of CANB. Prosperity, Radical Tactical, NY Hemp Depot and Green Grow Farms had no activity for the periods presented. Financial information for PHP and Duramed in the periods have been consolidated with the Company’s financials.

Going Concern Uncertainty

Going Concern Uncertainty	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainty	NOTE 2 – Going Concern Uncertainty The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of December 31, 2019, the Company had cash and cash equivalents of $46,540 and a working capital of $2,881,147. For the years ended December 31, 2019 and 2018, the Company had net loss of $4,592,470 and $4,112,277, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company plans to improve its financial condition by raising capital through sales of shares of its common stock. Also, the Company plans to expand its operation of CBD products to increase its profitability. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – Summary of Significant Accounting Policies (a) Principles of Consolidation The consolidated financial statements include the accounts of CANB and its wholly-owned subsidiaries, Pure Health Products, Duramed, Prosperity and Radical Tactical. All intercompany balances and transactions have been eliminated in consolidation. (b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. (c) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value. Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. (d) Cash and Cash Equivalents The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents. (e) Accounts receivable Accounts receivable are presented in the balance sheet net of the allowance for doubtful accounts. Accounts receivable are written off when they are determined to be uncollectible. The allowance for doubtful accounts is estimated based on the Company’s historical losses, the existing economic conditions in the industry, and the financial stability of its customers. Bad debt expense was $253,483 and $0 for the years ended December 31, 2019 and 2018. (f) Inventory Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method. (g) Prepaid expenses Prepaid expenses include stock-based officer, employee and consulting compensation of $2,459,830 and $2,576,070 at December 31, 2019 and 2018, respectively. The Company’s policy is to record stock-based compensation as prepaids and expense over the term of employment and consulting agreements. (h) Property and Equipment, Net Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred. (i) Intangible Assets, Net Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets. (j) Goodwill The Company does not amortize goodwill, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded. (k) Long-lived Assets The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. (l) Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts. Private Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped. Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis. (m) Cost of Product Sales The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products. (m) Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.” In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions. In accordance with ASC 505-50, the Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete. Options and warrants The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards. Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock. Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant. Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods. (o) Advertising Advertising costs are expensed as incurred and amounted to $333,441 and $84,316 for the years ended December 31, 2019 and 2018, respectively. (p) Research and Development Research and development costs are expensed as incurred. In the period ended December 31, 2019 and 2018, the Company spent $150,000 and $75,000 in research and development which was expenses as spent, respectively. (q) Income Taxes Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized. The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability. (r) Net Income (Loss) per Common Share Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 9, 10 and 11). (s) Recent Accounting Pronouncements In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption. As such, historical periods will continue to be measured and presented under the previous guidance while current and future periods subject to this new accounting guidance. Upon adoption we recorded a $100,681 right-of-use asset related to our one operating lease (see Note 14) and a $90,591 lease liability. (t) Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net income.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	NOTE 4 – Inventories Inventories consist of: December 31, December 31, Raw materials $ 708,239 $ 79,652 Finished goods 76,258 7,452 Total $ 784,497 $ 87,104

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Notes Receivable	NOTE 5 – Notes Receivable Notes receivable consist of: December 31, December 31, 2018 Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $ 19,389 $ 19,389 Note receivable dated February 8,2019 from an employee, weekly installments of $1,200 with interest at 8% per annum. 4,879 - Total 24,268 19,389 Current portion of notes receivable (24,268 ) - Noncurrent portion of notes receivable $ - $ 19,389

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 6 – Property and Equipment, Net Property and Equipment, net, consist of: December 31, 2019 December 31, 2018 Furniture & Fixtures $ 19,018 $ 19,018 Office Equipment 12,378 20,992 Manufacturing Equipment 355,016 46,384 Medical Equipment 783,782 - Leasehold Improvements 21,603 - Total 1,191,797 86,394 Accumulated depreciation (116,555 ) (26,775 ) Net $ 1,075,242 $ 59,619

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	NOTE 7 – Intangible Assets, Net Intangible assets, net, consist of: December 31, 2019 December 31, 2018 Video conferencing software acquired by Prosperity in December 2009 $ 30,000 $ 30,000 Enterprise and audit software acquired by Prosperity in April 2008 20,000 20,000 Patent costs incurred by WRAP 6,880 6,880 Hemp license and technology 1,000,000 - CBD technology 198,655 - Other 3,548 3,548 Total 1,259,083 60,428 Accumulated amortization and Impairment (202,521 ) (60,428 ) Net $ 1,056,562 $ - The CBD related technology were purchased from Hudilab, Inc. (“HUDI”) and Seven Chakras, LLC (“Seven Chakras”) during the three months ended March 31, 2019. On January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement (the “LAA”) with HUDI. Pursuant to the LAA, HUDI will sell the technology owned by it to the buyer in exchange for 7,500,000 (prior to 300:1 reverse split) shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of HUDI and valued at $131,625. On January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Chakras Agreement”) with Seven Chakras, LLC (“Seven Chakras”). Pursuant to the Chakras Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (“CBD”), (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials (collectively, the “Assets”). On February 20, 2019, the Company issued 1,000,000 (prior to 300:1 reverse split) shares of CANB common stock valued at $17,030 to owners of Seven Chakras as additional consideration, along with the $50,000 cash payments, pursuant to the Chakras Agreement. The hemp related license and technology purchased from Shi Farms during the three months ended September 30, 2019. Hemp Depot will contract with farmers in New York to grow hemp under a controlled program of specific strains, cultured feminized seeds, proven technology, and access to processing for their crop. NY Hemp Depot will amalgamate the cultivated off-take from the farmers, combine and fill “super-sacks” for shipping to the processing facility in Colorado to produce high-grade isolate or distillate for use in Can B’s manufacturing facility in Lacey WA. The other intangible assets relate to the document management and email marketing divisions. Since December 31, 2017, the Company do not expect any future positive cash flow from these divisions. Accordingly, the net carrying value of these intangible assets was reduced to $0.

Notes and Loans Payable

Notes and Loans Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes and Loans Payable	NOTE 8 – Notes and Loans Payable Notes and loans payable consist of: December 31, December 31, Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due) 5,000 5,000 Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021 - 10,899 Loan payable to McKenzie Webster Limited (“MWL”), non-interest bearing, due on demand. - 3,000 Loan payable to Pasquale Ferro, interest at 12% per annum, due December 2020. 30,000 - Total $ 35,000 $ 18,899

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Preferred Stock	NOTE 9 – Preferred Stock Note- The share and vote amounts referenced below are reflected prior to the 300:1 reverse split in March 2020. Each share of Series A Preferred Stock is convertible into 10,000,000 shares of CANB common stock and is entitled to 20,000,000 votes. Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights. On January 22, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share. On February 12, 2018, the Company issued 1 share of CANB Series A Preferred Stock to David Posel pursuant to a service agreement. The fair value of the issuance is $373,000 and will be amortized over the vesting period of four years. On February 16, 2018, the Company issued 3 shares of CANB Series A Preferred Stock to Andrew Holtmeyer pursuant to a service agreement. The fair value of the issuance is $1,020,000 and will be amortized over the vesting period of one year. On February 16, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share. On March 20, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share. On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, RedDiamond Partners converted its 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock to 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock, respectively. On May 14, 2018, the Company issued 1 share of CANB Series A Preferred Stock to a consultant pursuant to a Consulting Agreement dated May 11, 2018. The $150,000 fair value of the issuance was partially charged to consulting fees in the three months ended September 30, 2018. From July 24, 2018 to September 26, 2018, RedDiamond Partners converted aggregately 263,263 shares of CANB Series B Preferred Stock to 53,839,743 shares of CANB common stock. On August 28, 2018, September 14, 2018 and September 19, 2018, the Company issued 36,842 shares, 105,263 shares, and 105,263 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $35,000, $100,000 and $100,000, respectively, or $0.95 per CANB Series B Preferred share. From October 2, 2018 to November 7, 2018, RedDiamond Partners converted aggregately 101,736 shares of CANB Series B Preferred Stock to 13,094,733 shares of CANB common stock. On October 23, 2018 and November 14, 2018, the Company issued 200,000 shares and 52,500 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) in exchange for proceeds of $190,000 and $49,875, respectively, or $0.95 per CANB Series B Preferred share. On December 28,2018, Marco Alfonsi converted 3 shares of CANB Series A Preferred Stock to 30,000,000 shares of CANB common stock. On December 29, 2018 the Company issued 8 shares of CANB Series A Preferred Stock to three officers of the company (1 share to Stanley L. Teeple, 5 shares to Pasquale Ferro and 2 shares to Andrew Holtmeyer), pursuant to the employment agreements with them. The fair value of the issuance totaled at $4,624,000 and will be amortized over the vesting period of four years. On January 28, 2019, the Company issued 10,000,000 shares of CANB common stock to a consultant of the Company in exchange for the retirement of 1 share of CANB Series A Preferred Stock. From February 21, 2019 to March 12, 2019, the Company issued aggregately 20,221,436 shares of CANB common stock to RedDiamond in exchange for the retirement of 157,105 shares of CANB Series B Preferred Stock. On May 28, 2019, the Company issued 3 shares of CANB Series A Preferred Stock to Stanley L. Teeple pursuant to the employment agreement with him. The fair value of the issuance totaled at $1,203,000 and will be amortized over the vesting period of four years. On April 26, 2019, the Company issued 1,930,693 shares of CANB common stock to RedDiamond in exchange for the retirement of 15,000 shares of CANB Series B Preferred Stock. On May 1, 2019, the Company issued 2,574,257 shares of CANB common stock to RedDiamond in exchange for the retirement of 20,000 shares of CANB Series B Preferred Stock. On May 9, 2019, the Company issued 7,113,059 shares of CANB common stock to RedDiamond in exchange for the retirement of 55,263 shares of CANB Series B Preferred Stock. On June 7, 2019, the Company issued 3,217,822 shares of CANB common stock to RedDiamond in exchange for the retirement of 25,000 shares of CANB Series B Preferred Stock. On August 13, 2019, the Company issued 29,282,179 shares of CANB common stock to RedDiamond in exchange for the retirement of 227,590 shares of CANB Series B Preferred Stock. On December 16, 2019, the Company issued 10,700,000 shares of CANB common stock to RedDiamond as agreed for the early retirement of CANB Series B Preferred Stock converted in August 2019.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common Stock	NOTE 10 – Common Stock Note- The share amounts referenced below are reflected prior to the 300:1 reverse split in March 2020. On February 7, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $9,825 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018. On February 9, 2018, the Company issued 3,000,000 and 3,000,000 shares of CANB common stock to its two directors for services rendered, respectively. The $101,400 fair value of each 3,000,000 shares of CANB common stock was charged to directors fees in the three months ended March 31, 2018. The shares issued to one of the directors were converted to options at June 11, 2018 (see Note 11). On February 13, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,085 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018. On February 14, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018. On February 19, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,280 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018. On February 26, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,375 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018. On March 1, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,900 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018. On March 20, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,500 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018. On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, the Company issued 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock to RedDiamond in exchange for the retirement of 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock, respectively. On May 9, 2018, the Company issued 125,000 shares of CANB common stock to a consultant for services rendered. The $1,812 fair value of the 125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018. On May 29, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018. On May 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,600 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018. On June 4, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018. On June 11, 2018, the Company agreed to issue 2,749,429 shares of CANB common stock to a lender in satisfaction of notes payable of $15,000 and accrued interest payable of $4,246. The shares was issued at August 24, 2018. On June 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,250 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018. On June 22, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,250 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018. From July 24, 2018 to September 26, 2018, the Company issued aggregately 53,839,743 shares of CANB common stock to RedDiamond in exchange for the retirement of 263,263 shares of CANB Series B Preferred Stock. On July 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,225 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018. On August 9, 2018, Company received a conversion notice from a lender. As a result, 9,544,292 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $50,000 and accrued interest payable of $7,266 at August 21, 2018. On August 28, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $159,600 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 6, 2018, the Company issued 300,000 shares of CANB common stock to a consultant for services rendered. The $16,500 fair value of the 300,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 6, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $27,500 fair value of the 500,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018. On September 6, 2018, the Company issued 8,430,331 shares of CANB common stock to a lender in satisfaction of notes payable of $38,500 and accrued interest payable of $7,867. On September 7, 2018, the Company issued 5,121,694 shares of CANB common stock to a lender in satisfaction of notes payable of $25,000 and accrued interest payable of $3,169. On September 7, 2018, the Company issued 10,045,667 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $10,274. On September 8, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 10, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $19,950 fair value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 17, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $13,725 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 20, 2018, the Company issued 7,407,407 shares of CANB common stock to an investor pursuant to a Stock Purchase Agreement dated September 17, 2018, in exchange for proceeds of $200,000, or $0.027 per CANB common share. On September 21, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $14,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. On September 25, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $97,400 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018. From October 2, 2018 to November 7, 2018, the Company issued aggregately 13,094,733 shares of CANB common stock to RedDiamond in exchange for the retirement of 101,736 shares of CANB Series B Preferred Stock. From November 5, 2018 to December 28, 2018, the Company issued aggregately 2,125,000 shares of CANB common stock to multiple consultants for services rendered. The $80,665 fair value of the 2,125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 30, 2018. From December 3, 2018 to December 28, 2018, the Company issued aggregately 1,500,000 shares of CANB common stock to three board members for services rendered. The $62,342 fair value of the 1,500,000 shares of CANB common stock was charged to director fees in the three months ended December 30, 2018. From December 3, 2018 to December 28, 2018, the Company issued aggregately 22,413,794 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $650,000. On December 11, 2018, the Company issued 891,089 shares of CANB common stock to RedDiamond in satisfaction of dividend payable of $9,000. On December 19, 2018, the Company issued 891,089 shares of CANB common stock to Auctus, LLC pursuant to a cashless exercise of stock options. On December 21, 2018, Company received a conversion notice from a lender. As a result, 9,372,100 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $83,500 and accrued interest payable of $10,221. On December 21, 2018, Company issued aggregately 4,370,629 shares of CANB common stock to four officers of the Company in satisfaction of accrued compensation of $192,300. On December 28, 2018, the Company issued 3,096,827 shares of CANB common stock for the acquisition of Pure Health Products, LLC. On December 28, 2018, the Company issued 245,789 shares of CANB common stock to an officer of the Company pursuant to the Employment Agreement dated December 29, 2018 with Andrew Holtmeyer. The $10,371 fair value of the issuance was charged to stock-based compensation in the three months ended December 31, 2018. On December 29, the Company issued 30,000,000 shares of CANB common stock to Marco Alfonsi in exchange for the return of 3 shares of CANB Series A Preferred Stock owned by Marco Alfonsi. From January 4, 2019 to March 27, 2019, the Company issued aggregately 41,431,994 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100. On January 14, 2019, the Company issued 7,500,000 shares of CANB common stock to Hudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the technology owned by HUDI. From January 18, 2019 to March 17, 2019, the Company issued aggregately 24,600,000 shares of CANB common stock to multiple consultants for services rendered. From January 19, 2019 to March 27, 2019, the Company issued aggregately 1,167,959 shares of CANB common stock to employee and officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019. On February 5, 2019, the Company issued 2,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018. On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to owners of Seven Chakras pursuant to an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC dated January 31, 2019. From April 1, 2019 through June 30, 2019 the company issued an aggregate of 15,511,767 shares of CANB Common Stock to multiple consultants for services rendered. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 4,174,886 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 1,384,621 shares of Common Stock under the terms of executive employment agreements. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 25,862,071 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $750,000. From July 1, 2019 through September 30, 2019, the company issued an aggregate of 5,418,301 shares of CANB Common Stock to multiple consultants for services rendered. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 5,500,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 4,800,000 shares of Common Stock under the terms of executive employment agreements. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 46,572,416 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $1,350,600. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 12,074,089 shares of CANB shares under the terms of the Joint Venture Agreement. From October 1, 2019 through December 31, 2019, the company issued an aggregate of 36,677,274 shares of CANB Common Stock to multiple consultants for services rendered. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 4,250,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 1,500,000 shares of Common Stock under the terms of executive employment agreements. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 37,500,000 shares of CANB Common Stock under the terms of an inventory purchase agreement for total proceeds of $487,500.

Stock Options and Warrants - Pr

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Options and Warrants - Prior to 300:1 Reverse Stock Split	NOTE 11 – Stock Options and Warrants – Prior to 300:1 reverse stock split A summary of stock options and warrants activity follows: Shares of Common Stock Exercisable Into Stock Options Warrants Total Balance, December 31, 2017 50,000 247,500 297,500 Granted in 2018 6,000,000 2,850,000 8,850,000 Cancelled in 2018 - - - Exercised in 2018 - (850,000 ) (850,000 ) Balance, December 31, 2018 6,050,000 2,247,500 8,297,500 Granted in Q1, Q2 & Q3 2019 17,000,000 - 17,000,000 Cancelled in Q1, Q2 Q3, & Q4 2019 (50,000 ) - (50,000 ) Exercised in Q1, Q2 Q3, & Q4 2019 - - - Balance, December 31, 2019 23,000,000 2,247,500 25,247,500 Issued and outstanding stock options as of December 31, 2019 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2018 6,000,000 $ 0.001 2023 2019 17,000,000 $ 0.001 2022 23,000,000 On June 11, 2018, the Company granted 3,000,000 options of CANB common stock to Carl Dilley, a former director of the Company, in exchange for the retirement of a total of 3,000,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.028 share price, (ii) 5 years term, (iii) 262.00% expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares was expensed in the quarterly period ended June 30, 2018. On October 21, 2018, the Company granted 3,000,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023. The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.0395 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2018 On September 9, 2019, the Company granted 8,000,000 options of CANB common stock to Johnny Mack, a former officer of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire September 9, 2022. The values of the Stock Options ($192,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.024 share price, (ii) 3 years term, (iii) 242% expected volatility, (iv) 1.46% risk free interest rate and the fair value of options was expensed in the quarterly period ended September 30, 2019. On October 15, 2019, the Company granted 3,000,000 options of CANB common stock each to Frederick Alger Boyer, Jr., Ronald A. Silver and James F. Murphy, directors of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 15, 2022. The values of the Stock Options ($63,000 each) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.021 share price, (ii) 3 years term, (iii) 242% expected volatility, (iv) 1.60% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2019. Issued and outstanding warrants as of December 31, 2019 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2010 247,500 $ 1.00 2020 2018 2,000,000 $ 0.04345 (a) 2023 Total 2,247,500 (a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12 – Income Taxes No provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods. The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% to pretax income (loss) as follows: December 31, 2019 2018 Expected income tax (benefit) at 21% $ (964,419 ) $ (863,578 ) Non-deductible stock-based compensation 648,729 583,653 Non-deductible amortization of debt discounts - 37,064 Loss on stock issuance - 136,344 Loss on debt conversion - 272,867 Non-deductible expense from derivative liability - (334,139 ) Loan forgiveness - 18,024 Increase in deferred income tax assets valuation allowance 315,690 149,765 Provision for (benefit from) income taxes $ - $ - Deferred income tax assets consist of: December 31, December 31, 2019 2018 Net operating loss carryforward 1,300,168 984,478 Valuation allowance (1,300,168 ) (984,478 ) Net $ - $ - Based on management’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income tax asset of $1,300,168 attributable to the future utilization of the $6,191,273 net operating loss carryforward as of December 31, 2019 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the financial statements at December 31, 2019. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038 and 2039 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890, $25,511, $338,345, $381,638, $499,288, $716,858 and $1,503,282, respectively. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. The Company’s U.S. Federal and state income tax returns prior to 2015 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations on the 2015 tax year returns expired in September 2019. The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest or penalties paid during 2019 and 2018.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	NOTE 13 – Segment Information The Company has one reportable segment: Durable Equipment Products. The accounting policies of the segment described above are the same as those described in Summary of Significant Accounting Policies in Note 3. The Company evaluates the performance of the Durable Equipment Products segment based on income (loss) before income taxes, which includes interest income. Durable Equipment Products Three months ended December 31, 2019 Revenue from external customers 466,920 Revenue from other segments - Segment profit 309,370 Segment assets 1,994,845 Twelve months ended December 31, 2019 Revenue from external customers 1,436,403 Revenue from other segments - Segment profit 809,631 Segment assets 1,994,845 Three Months Ended December 31, 2019 Twelve Months Ended December 31, 2019 Total profit for reportable segment $ 309,208 $ 810,060 Other income (expense) - net 162 (429 ) Income before income taxes $ 309,370 $ 809,631

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14 – Commitments and Contingencies Employment Agreements On October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company’s chief executive officer and interim chief financial officer and secretary for cash compensation of $10,000 per month. Pursuant to the agreement, the Company issued a share of CANB Series A Preferred Stock to Alfonsi on October 4, 2017 (see Note 9). Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate Alfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At October 21, 2018, this former Agreement was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s chief executive officer for cash compensation of $15,000 per month. Pursuant to the new Agreement, three of the eight previously issued shares of CANB Series A Preferred Stock will be returned to the Company and converted into 30,000,000 common shares. On December Alfonsi may terminate his employment upon 30 days written notice to the Company. The new Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance. On February 12, 2018, the Company executed an Executive Service Agreement (“Agreement”) with David Posel. The Agreement provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Agreement also provides for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel (see Note 9). Since execution of the Posel Agreement, Mr. Posel has been re-assigned to COO for Pure Health Products, the Company’s subsidiary. On February 16, 2018, the Company executed an Executive Service Agreement (“Agreement”) with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 3 years. The Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of Series A Preferred Stock at the beginning of each year. The Agreement can be terminated upon the resignation or death of Mr. Holtmeyer, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the misconduct of Mr. Holtmeyer in connection with the performance. At December 29, 2018, this Agreement was terminated due to the execution of a new Employment Agreement with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 4 years. The Agreement also provides for compensation to Mr. Holtmeyer of $15,000 cash per month and the issuance of 245,789 shares of common stock (prior to 300:1 reverse stock split) upon signing of the agreement. On October 15, 2018, the Company executed an Employment Agreement (“Agreement”) with Stanley L. Teeple. The Agreement provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock proportionately vesting over four years beginning December 31, 2018 upon execution of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be terminated by the Company due to the failure or neglect of Mr. Teeple to perform his duties, or due to the misconduct of Mr. Teeple in connection with the performance. In May 2019 Mr. Teeple was granted an additional 3 shares of Series A Preferred. On December 28, 2018, the Company executed an Employment Agreement (“Agreement”) with Pasquale Ferro for Mr. Ferro to serve as Pure Health Products’ president for cash compensation of $15,000 per month and the total issuance of 5 share of Series A Preferred Stock proportionately vesting at the beginning of each year for a term of 4 years. Mr. Ferro may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Ferro, and also can be terminated by the Company due to the failure or neglect of Mr. Ferro to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance. Effective September 6, 2019 (the “Effective Date”), Can B̅ Corp (the “Company” or “CANB”) approved the appointment of Johnny J. Mack (“Mack”) as its President and Chief Operating Officer. Mack had been serving as the Company’s interim COO. The Company and Mack have entered into a new Employee Services Agreement (the “Agreement”) to memorialize the terms of the foregoing. In consideration for Mack’s services, Mack will (i) receive a base salary of $15,000 per month, subject to increase after each yearly anniversary of the Agreement, (ii) be eligible to receive annual cash or stock bonuses, (iii) be entitled to four weeks’ vacation time and five paid days for illness in accordance with the Company’s policies, and (iv) receive a total of 32,000,000 options (“Options”) to purchase shares of the Company’s common stock, with 8,000,000 Options vesting on the effective date and additional tranches of 8,000,000 Options vesting on each of the first, second, and third anniversaries of the Effective Date, assuming Mack’s continued employment. Each Option is exercisable at a price of $0.001 per share (prior to 300:1 reverse stock split). The Company also agreed to hold harmless and indemnify Mack as authorized or permitted by law and the Company’s governing documents, as the same may be amended from time to time, except for acts constituting negligence or willful misconduct by Mack. The Company has agreed to pay Mack a severance in the event the Agreement is terminated by the Company without cause or by Mack for “good reason” or by reason of Mack’s death or disability. On October 4, 2019 Mack resigned from all of his office and director positions and the company settled his termination for payment of all accrued expenses, payout of all accrued time and base compensation of $13,315 and retention of his already earned 8 million options. Mr. Mack has left the Company. In addition, on October 10th, 2019 the Company appointed Philip Scala as its interim COO. Mr. Scala has acted as founder and CEO of Pathfinder Consultants International, Inc. (“Pathfinder”) since 2008. Pathfinder offers unique expertise and delivers the information you need to make informed decisions, whether in times of crisis or in the course of simply running your business. Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his 29 years of service with the FBI. Mr. Scala received his bachelor’s degree and Master of Business Administration in accounting from St. John’s University, he also earned a Master of Arts degree in Psychology from New York University. The Company has entered into an employment agreement with Mr. Scala. Pursuant to the agreement, Mr. Scala will receive a base salary of $2,500 per month. He will be entitled to incentive bonuses and pay increases in accordance with the Company’s normal policies and procedures. Mr. Scala will also receive options to buy 500,000 common shares of the Company at a price of $0.001 (prior to 300:1 reverse stock split) for a period of three years. The initial term of the agreement is for 90 days. The agreement otherwise contains standard covenants and conditions. Consulting Agreements On September 6, 2017, the Company executed a Consulting Agreement with T8 Partners LLC (“T8”) for T8 to serve as the Company’s consultant for stock compensation of a total of 10,000,000 restricted shares (prior to 300:1 reverse stock split). Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to T8 on September 7, 2017. Effective October 27, 2017, the Company terminated the agreement due to non-performance by T8. The Company won the arbitration proceedings against T8 and T8 has been ordered to return its shares to the Company. On November 9, 2017, the Company executed a Consulting Agreement with Healthcare Advisory Group Company (“Healthcare”) for Healthcare to serve as the Company’s consultant for stock compensation of a total of 5,000,000 restricted shares (prior to 300:1 reverse stock split). Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to Healthcare on November 9, 2017. Effective March 6, 2018, the Company terminated the agreement due to non-performance by Healthcare. On April 1, 2019, we engaged an advisor to provide consulting services under an Investor Relations and Advisory Agreement (the “Advisory Agreement”). Pursuant to the Advisory Agreement, we agreed to pay the Consulting Firm a restricted common stock monthly fee of $5,500 per month for consulting and services paid in advance of services each month. Starting May 1, 2019, the restricted common stock monthly fee will decrease to $4,000 per month. The number of shares to be issued will be calculated based on the closing price of our common shares on the 1st or preceding day of each month, if the 1st were to fall on a weekend or holiday. The shares shall not have registration rights, and the shares may be sold subject to Rule 144. Lease Agreements On December 1, 2014, Prosperity entered into a lease agreement with KLAM, Inc. for office space in Hicksville, New York for an initial term of one year commencing December 1, 2014. The lease provides for monthly rentals of $2,500 and provides Prosperity an option to renew the lease after the initial term. The Company has continued to occupy this space after November 30, 2015 under a month to month arrangement at $2,500 per month. On September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100 for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3. In October 2019, the Company modified and extended the lease agreement for a term of 30 months starting November 1, 2019. The lease provides for monthly rentals of $3,807.05 for year 1 and $3,921.26 for the remaining eighteen months. The original $100,681 right-of-use asset and $90,591 lease liability was adjusted to $103,260 with the modification. The Company leases office space in numerous medical facilities under month-to-month agreements. Rent expense for the years ended December 31, 2019 and 2018 was $246,968 and $67,165, respectively. At December 31, 2019, the future minimum lease payments under non-cancellable operating leases were: Year ended December 31, 2020 $ 45,913 Year ended December 31, 2021 47,055 Year ended December 31, 2022 15,685 Total $ 108,653 The lease liability of $97,279 at December 31, 2019 as presented in the Consolidated Balance Sheet represents the discounted (at our 10% estimated incremental borrowing rate) value of the future lease payments of 108,653 at December 31, 2019. Major Customers For the twelve months ended December 31, 2019, there were no customers that accounted for more than 10% of total revenues. For the twelve months ended December 31, 2018, one customer accounted for approximately 16% of total revenues.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 15 – Related Party Transactions LI Accounting Associates, LLC (LIA), an entity controlled by a relative of the Managing Member PHP, is a vendor of CANB. At December 31, 2019, CANB did not have an account payable due to LIA. For the twelve months ended December 31, 2019, CANB had expenses to LIA of $10,750. During the twelve months ended December 31, 2019, we had products and service sales to related parties totaling $0.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 17 – Subsequent Events In accordance with FASB ASC 855, Subsequent Events, the Company has evaluated subsequent events through November 1, 2019, the date on which these consolidated financial statements were available to be issued. There were material subsequent events that required recognition or additional disclosure in these consolidated financial statements as follows: The Company acquired 51% of Green Grow Farms, Inc. (GGFI) in December 2019 for 37.5 million shares of CANB common stock. The remaining 49% of GGFI was held by New York Farm Group (NYFG). Post-closing of the original agreement, the Company discovered certain assets needed reassessment and reconsideration. In settlement of certain claims held by the Company as a result of the foregoing, NYFG agreed to assign the Company its 49% interest in GGFI and 1,000,000 shares of Iconic Brands, Inc (ICNB) stock in consideration for a release from the Company. The settlement agreement was executed on March 3, 2020. On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the year ended December 31, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	(a) Principles of Consolidation The consolidated financial statements include the accounts of CANB and its wholly-owned subsidiaries, Pure Health Products, Duramed, Prosperity and Radical Tactical. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	(b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Fair Value of Financial Instruments	(c) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value. Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Cash and Cash Equivalents	(d) Cash and Cash Equivalents The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.
Accounts Receivable	(e) Accounts receivable Accounts receivable are presented in the balance sheet net of the allowance for doubtful accounts. Accounts receivable are written off when they are determined to be uncollectible. The allowance for doubtful accounts is estimated based on the Company’s historical losses, the existing economic conditions in the industry, and the financial stability of its customers. Bad debt expense was $253,483 and $0 for the years ended December 31, 2019 and 2018.
Inventory	(f) Inventory Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method.
Prepaid Expenses	(g) Prepaid expenses Prepaid expenses include stock-based officer, employee and consulting compensation of $2,459,830 and $2,576,070 at December 31, 2019 and 2018, respectively. The Company’s policy is to record stock-based compensation as prepaids and expense over the term of employment and consulting agreements.
Property and Equipment, Net	(h) Property and Equipment, Net Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.
Intangible Assets, Net	(i) Intangible Assets, Net Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets.
Goodwill	(j) Goodwill The Company does not amortize goodwill, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded.
Long-lived Assets	(k) Long-lived Assets The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.
Revenue Recognition	(l) Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts. Private Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped. Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.
Cost of Product Sales	(m) Cost of Product Sales The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products.
Stock-Based Compensation	(m) Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.” In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions. In accordance with ASC 505-50, the Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete. Options and warrants The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards. Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock. Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant. Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.
Advertising	(o) Advertising Advertising costs are expensed as incurred and amounted to $333,441 and $84,316 for the years ended December 31, 2019 and 2018, respectively.
Research and Development	(p) Research and Development Research and development costs are expensed as incurred. In the period ended December 31, 2019 and 2018, the Company spent $150,000 and $75,000 in research and development which was expenses as spent, respectively.
Income Taxes	(q) Income Taxes Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized. The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability.
Net Income (Loss) Per Common Share	(r) Net Income (Loss) per Common Share Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 9, 10 and 11).
Recent Accounting Pronouncements	(s) Recent Accounting Pronouncements In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption. As such, historical periods will continue to be measured and presented under the previous guidance while current and future periods subject to this new accounting guidance. Upon adoption we recorded a $100,681 right-of-use asset related to our one operating lease (see Note 14) and a $90,591 lease liability.
Reclassifications	(t) Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net income.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of: December 31, December 31, Raw materials $ 708,239 $ 79,652 Finished goods 76,258 7,452 Total $ 784,497 $ 87,104

Notes Receivable (Tables)

Notes Receivable (Tables)	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Schedule of Notes Receivable	Notes receivable consist of: December 31, December 31, 2018 Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $ 19,389 $ 19,389 Note receivable dated February 8,2019 from an employee, weekly installments of $1,200 with interest at 8% per annum. 4,879 - Total 24,268 19,389 Current portion of notes receivable (24,268 ) - Noncurrent portion of notes receivable $ - $ 19,389

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	Property and Equipment, net, consist of: December 31, 2019 December 31, 2018 Furniture & Fixtures $ 19,018 $ 19,018 Office Equipment 12,378 20,992 Manufacturing Equipment 355,016 46,384 Medical Equipment 783,782 - Leasehold Improvements 21,603 - Total 1,191,797 86,394 Accumulated depreciation (116,555 ) (26,775 ) Net $ 1,075,242 $ 59,619

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	Intangible assets, net, consist of: December 31, 2019 December 31, 2018 Video conferencing software acquired by Prosperity in December 2009 $ 30,000 $ 30,000 Enterprise and audit software acquired by Prosperity in April 2008 20,000 20,000 Patent costs incurred by WRAP 6,880 6,880 Hemp license and technology 1,000,000 - CBD technology 198,655 - Other 3,548 3,548 Total 1,259,083 60,428 Accumulated amortization and Impairment (202,521 ) (60,428 ) Net $ 1,056,562 $ -

Notes and Loans Payable (Tables

Notes and Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Notes and Loans Payable	Notes and loans payable consist of: December 31, December 31, Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due) 5,000 5,000 Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021 - 10,899 Loan payable to McKenzie Webster Limited (“MWL”), non-interest bearing, due on demand. - 3,000 Loan payable to Pasquale Ferro, interest at 12% per annum, due December 2020. 30,000 - Total $ 35,000 $ 18,899

Stock Options and Warrants - _2

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of Stock Options and Warrants Activity	A summary of stock options and warrants activity follows: Shares of Common Stock Exercisable Into Stock Options Warrants Total Balance, December 31, 2017 50,000 247,500 297,500 Granted in 2018 6,000,000 2,850,000 8,850,000 Cancelled in 2018 - - - Exercised in 2018 - (850,000 ) (850,000 ) Balance, December 31, 2018 6,050,000 2,247,500 8,297,500 Granted in Q1, Q2 & Q3 2019 17,000,000 - 17,000,000 Cancelled in Q1, Q2 Q3, & Q4 2019 (50,000 ) - (50,000 ) Exercised in Q1, Q2 Q3, & Q4 2019 - - - Balance, December 31, 2019 23,000,000 2,247,500 25,247,500
Schedule of Issued and Outstanding Stock Options	Issued and outstanding stock options as of December 31, 2019 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2018 6,000,000 $ 0.001 2023 2019 17,000,000 $ 0.001 2022 23,000,000
Schedule of Issued and Outstanding Warrants	Issued and outstanding warrants as of December 31, 2019 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2010 247,500 $ 1.00 2020 2018 2,000,000 $ 0.04345 (a) 2023 Total 2,247,500 (a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Provisions for (Benefits from) Income Taxes	The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% to pretax income (loss) as follows: December 31, 2019 2018 Expected income tax (benefit) at 21% $ (964,419 ) $ (863,578 ) Non-deductible stock-based compensation 648,729 583,653 Non-deductible amortization of debt discounts - 37,064 Loss on stock issuance - 136,344 Loss on debt conversion - 272,867 Non-deductible expense from derivative liability - (334,139 ) Loan forgiveness - 18,024 Increase in deferred income tax assets valuation allowance 315,690 149,765 Provision for (benefit from) income taxes $ - $ -
Schedule of Deferred Income Tax Assets	Deferred income tax assets consist of: December 31, December 31, 2019 2018 Net operating loss carryforward 1,300,168 984,478 Valuation allowance (1,300,168 ) (984,478 ) Net $ - $ -

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The Company evaluates the performance of the Durable Equipment Products segment based on income (loss) before income taxes, which includes interest income. Durable Equipment Products Three months ended December 31, 2019 Revenue from external customers 466,920 Revenue from other segments - Segment profit 309,370 Segment assets 1,994,845 Twelve months ended December 31, 2019 Revenue from external customers 1,436,403 Revenue from other segments - Segment profit 809,631 Segment assets 1,994,845 Three Months Ended December 31, 2019 Twelve Months Ended December 31, 2019 Total profit for reportable segment $ 309,208 $ 810,060 Other income (expense) - net 162 (429 ) Income before income taxes $ 309,370 $ 809,631

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases	At December 31, 2019, the future minimum lease payments under non-cancellable operating leases were: Year ended December 31, 2020 $ 45,913 Year ended December 31, 2021 47,055 Year ended December 31, 2022 15,685 Total $ 108,653

Organization and Description _2

Organization and Description of Business (Details Narrative)	Mar. 31, 2020	Mar. 06, 2020	Jun. 04, 2013	Dec. 27, 2010	Dec. 31, 2019	Dec. 28, 2018	Jan. 05, 2015
State of incorporated					Florida
Entity date of incorporation					Oct. 11, 2005
Stockholders' equity, stock split				10 for 1 forward stock split
Stockholders' equity, reverse stock split			1 for 10 reverse stock split
Subsequent Event [Member]
Stockholders' equity, reverse stock split	300:1 reverse split	300:1 reverse split
Prosperity Systems, Inc [Member]
Business acquisition, percentage							100.00%
Pure Health Products, LLC [Member]
Business acquisition, percentage						100.00%

Going Concern Uncertainty (Deta

Going Concern Uncertainty (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 46,540	$ 807,747
Working capital	2,881,147
Net income loss	$ 4,592,470	$ 4,112,277

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 02, 2019
Accounting Policies [Abstract]
Bad debt expense	$ 253,483	$ 0
Prepaid expenses	2,459,830	2,576,070
Advertising expense	333,441	84,316
Research and development cost	150,000	75,000
Operating lease, right-of-use asset	96,980		$ 100,681
Lease liability	$ 97,279		$ 90,591

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 708,239	$ 79,652
Finished goods	76,258	7,452
Total	$ 784,497	$ 87,104

Notes Receivable - Schedule of

Notes Receivable - Schedule of Notes Receivable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Note receivable, Total	$ 24,268	$ 19,389
Current portion of notes receivable	(24,268)
Noncurrent portion of notes receivable		19,389
Employee [Member]
Note receivable, Total	4,879
Stock Market Manager, Inc [Member]
Note receivable, Total	$ 19,389	$ 19,389

Notes Receivable - Schedule o_2

Notes Receivable - Schedule of Notes Receivable (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee [Member]
Note receivable interest rate	8.00%
Installments	$ 1,200
Stock Market Manager, Inc [Member]
Notes receivable due date	Nov. 30, 2020	Nov. 30, 2020
Note receivable interest rate	3.00%	3.00%

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Furniture & Fixtures	$ 19,018	$ 19,018
Office Equipment	12,378	20,992
Manufacturing Equipment	355,016	46,384
Medical Equipment	783,782
Leasehold Improvements	21,603
Total	1,191,797	86,394
Accumulated depreciation	(116,555)	(20,248)
Net	$ 1,075,242	$ 59,619

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($)	Feb. 20, 2019	Jan. 14, 2019	Dec. 31, 2019	Dec. 31, 2018
Cash payments			$ 550,000	$ 46,384
Intangible assets, net			$ 0
License and Acquisition Agreement [Member] | Hudilab, Inc. [Member]
Shares issued to acquire assets		7,500,000
Shares issued to acquire assets, value		$ 131,625
Asset Purchase Agreement [Member] | Seven Chakras, LLC [Member]
Shares issued to acquire assets	1,000,000
Shares issued to acquire assets, value	$ 17,030
Cash payments	$ 50,000

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets and Goodwill (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Patent costs incurred by WRAP	$ 6,880	$ 6,880
Hemp license and technology	1,000,000
CBD technology	198,655
Other	3,548	3,548
Total	1,259,083	60,428
Accumulated amortization and Impairment	(202,521)	(60,428)
Net	1,056,562
Video Conferencing Software Acquired by Prosperity in December 2009 [Member]
Software acquired	30,000	30,000
Enterprise and Audit Software Acquired by Prosperity in April 2008 [Member]
Software acquired	$ 20,000	$ 20,000

Notes and Loans Payable - Sched

Notes and Loans Payable - Schedule of Notes and Loans Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Notes and loans payable	$ 35,000	$ 19,205
Notes Payable One [Member]
Notes and loans payable	5,000	5,000
Notes Payable Two [Member]
Notes and loans payable		10,899
Loan Payable One [Member]
Notes and loans payable		3,000
Loan Payable Two [Member]
Notes and loans payable	$ 30,000

Notes and Loans Payable - Sch_2

Notes and Loans Payable - Schedule of Notes and Loans Payable (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Notes Payable One [Member]
Debt instrument, interest rate	10.00%	10.00%
Debt instrument, maturity date	Aug. 22, 2016	Aug. 22, 2016
Notes Payable Two [Member]
Debt instrument, interest rate	12.99%	12.99%
Debt instrument, maturity date	Feb. 1, 2021	Feb. 1, 2021
Loan Payable Two [Member]
Debt instrument, interest rate	12.00%	12.00%
Debt instrument, maturity date	Dec. 31, 2020	Dec. 31, 2020

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Mar. 31, 2020	Mar. 06, 2020	Dec. 16, 2019	Aug. 13, 2019	Jun. 07, 2019	May 28, 2019	May 09, 2019	May 01, 2019	Apr. 26, 2019	Jan. 28, 2019	Dec. 29, 2018	Dec. 28, 2018	Nov. 14, 2018	Oct. 23, 2018	Oct. 15, 2018	Sep. 19, 2018	Sep. 14, 2018	Aug. 28, 2018	May 14, 2018	Mar. 20, 2018	Feb. 16, 2018	Feb. 12, 2018	Jan. 22, 2018	Jun. 04, 2013	May 31, 2019	Mar. 12, 2019	Dec. 31, 2019	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 07, 2018	Sep. 26, 2018	Jun. 25, 2018	Jun. 19, 2018	May 03, 2018	Apr. 25, 2018	Apr. 13, 2018
Stockholders' equity, reverse stock split																								1 for 10 reverse stock split
Proceeds from issuance of preferred stock																														$ 723,875
Shares issued during the period, value																													$ 3,296,700	$ 850,000
Common Stock [Member]
Shares issued during the period																													113,866,481	29,821,201
Shares issued during the period, value																													$ 3,296,700	$ 850,000
Consultant [Member]
Stock issued during period, shares, issued for services																											36,677,274
Consultant [Member] | Common Stock [Member]
Stock issued during period, shares, issued for services										10,000,000
RedDiamond Partners LLC [Member] | Common Stock [Member]
Number of convertible shares																															13,094,733	53,839,743
Shares issued during the period			10,700,000	29,282,179	3,217,822		7,113,059	2,574,257	1,930,693																	20,221,436
RedDiamond Partners LLC [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Number of convertible shares																																	2,363,636	3,545,455	1,287,129	1,287,129	1,287,129
Marco [Member] | Common Stock [Member]
Number of convertible shares												30,000,000
Series A Preferred Stock [Member]
Number of convertible shares																											10,000,000		10,000,000
Common stock, voting rights																													Each share of Series A Preferred Stock is convertible into 10,000,000 shares of CANB common stock and is entitled to 20,000,000 votes.
Number of voting rights per share																													20,000,000
Series A Preferred Stock [Member] | Andrew Holtmeyer [Member]
Shares issued during the period											2
Series A Preferred Stock [Member] | Three Officers [Member]
Shares issued during the period											8
Amortized vesting period											4 years
Shares issued during the period, value											$ 4,624,000
Series A Preferred Stock [Member] | Stanley L. Teeple [Member]
Shares issued during the period											1
Series A Preferred Stock [Member] | Pasquale Ferro [Member]
Shares issued during the period											5
Series A Preferred Stock [Member] | Consultant [Member]
Stock issued in exchange for retirement of shares										1
Series A Preferred Stock [Member] | Service Agreement [Member] | David Posel [Member]
Shares issued during the period																						1
Proceeds from issuance of preferred stock																						$ 373,000
Amortized vesting period																						4 years
Series A Preferred Stock [Member] | Service Agreement [Member] | Andrew Holtmeyer [Member]
Shares issued during the period																					3
Proceeds from issuance of preferred stock																					$ 1,020,000
Amortized vesting period																					1 year
Series A Preferred Stock [Member] | Consulting Agreements [Member]
Shares issued during the period																			1
Shares issued during the period, value																												$ 150,000
Series A Preferred Stock [Member] | Employment Agreement [Member] | Stanley L. Teeple [Member]
Shares issued during the period						3
Proceeds from issuance of preferred stock						$ 1,203,000
Amortized vesting period						4 years
Stock issued during period, shares, issued for services															1										3
Series A Preferred Stock [Member] | Employment Agreement [Member] | Pasquale Ferro [Member]
Stock issued during period, shares, issued for services												5
Series A Preferred Stock [Member] | Marco [Member]
Number of convertible shares												3
Series B Preferred Stock [Member]
Dividend, description																													Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.
Preferred stock, dividend rate, percentage																													5.00%
Preferred stock, voting rights																													The shares of Series B Preferred Stock have no voting rights.
Series B Preferred Stock [Member] | RedDiamond Partners LLC [Member]
Number of convertible shares																															101,736	263,263
Shares issued during the period													52,500	200,000
Proceeds from issuance of preferred stock													$ 49,875	$ 190,000
Shares issued, price per share													$ 0.95	$ 0.95
Stock issued in exchange for retirement of shares				227,590	25,000		55,263	20,000	15,000																	157,105
Series B Preferred Stock [Member] | RedDiamond Partners LLC [Member] | Securities Purchase Agreement [Member]
Number of convertible shares																																	10,000	15,000	10,000	10,000	10,000
Shares issued during the period																105,263	105,263	36,842		87,368	87,368		87,368
Proceeds from issuance of preferred stock																$ 100,000	$ 100,000	$ 35,000		$ 83,000	$ 83,000		$ 83,000
Shares issued, price per share																$ 0.95	$ 0.95	$ 0.95		$ 0.95	$ 0.95		$ 0.95
Subsequent Event [Member]
Stockholders' equity, reverse stock split	300:1 reverse split	300:1 reverse split

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)

Mar. 31, 2020

Mar. 06, 2020

Feb. 20, 2019

Feb. 05, 2019

Jan. 28, 2019

Jan. 14, 2019

Dec. 29, 2018

Dec. 28, 2018

Dec. 21, 2018

Dec. 19, 2018

Dec. 11, 2018

Sep. 25, 2018

Sep. 21, 2018

Sep. 20, 2018

Sep. 18, 2018

Sep. 17, 2018

Sep. 10, 2018

Sep. 08, 2018

Sep. 07, 2018

Sep. 06, 2018

Aug. 28, 2018

Aug. 21, 2018

Jul. 31, 2018

Jun. 25, 2018

Jun. 22, 2018

Jun. 19, 2018

Jun. 18, 2018

Jun. 11, 2018

Jun. 04, 2018

May 31, 2018

May 29, 2018

May 09, 2018

May 03, 2018

Apr. 25, 2018

Apr. 13, 2018

Mar. 20, 2018

Mar. 01, 2018

Feb. 26, 2018

Feb. 19, 2018

Feb. 14, 2018

Feb. 13, 2018

Feb. 09, 2018

Feb. 07, 2018

Jun. 04, 2013

Dec. 28, 2018

Nov. 07, 2018

Mar. 27, 2019

Mar. 17, 2019

Dec. 28, 2018

Sep. 26, 2018

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 27, 2019

Dec. 31, 2018

Dec. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Stockholders' equity, reverse stock split

1 for 10 reverse stock split

Fair value of common stock charged to fees of related period

$ 287,441

$ 117,718

Proceeds from issuance of common stock

$ 3,296,700

$ 850,000

Common stock, shares issued for cashless exercise of stock options

850,000

Fair value of common stock charged to stock-based compensation

$ 3,089,188

$ 2,779,300

Stock issued during the period, value

$ 3,296,700

$ 850,000

Consultant [Member]

Stock issued during period, shares, issued for services

36,677,274

Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

4,250,000

Stock Purchase Agreement [Member]

Stock issued during the period

46,572,416

25,862,071

Proceeds from issuance of common stock

$ 1,350,600

$ 750,000

Stock Purchase Agreement [Member] | Multiple Investors [Member]

Stock issued during the period

41,431,994

Stock issued during the period, value

$ 1,196,100

Executive Employment Agreements [Member]

Stock issued during period, shares, issued for services

1,500,000

4,800,000

1,384,621

Joint Venture Agreement [Member]

Stock issued during the period

12,074,089

Investor Purchase Agreement [Member]

Stock issued during period, shares, issued for services

37,500,000

Proceeds from issuance of common stock

$ 487,500

Common Stock [Member]

Stock issued during the period

113,866,481

29,821,201

Stock retired during period, shares

(3,000,000)

Stock issued during the period, value

$ 3,296,700

$ 850,000

Common Stock [Member] | Multiple Investors [Member]

Stock issued during period, shares, issued for services

24,600,000

Common Stock [Member] | Consultant [Member]

Stock issued during period, shares, issued for services

10,000,000

Common Stock [Member] | New Employment Agreement [Member] | Andrew W Holtmeyer [Member]

Stock issued during period, shares, issued for services

245,789

Fair value of common stock charged to stock-based compensation

$ 10,371

Common Stock [Member] | New Employment Agreement [Member] | Marco [Member]

Stock issued during period, shares, issued for services

30,000,000

Common Stock [Member] | Employee Agreement [Member] | Employees and Officers [Member]

Stock issued during period, shares, issued for services

1,167,959

Pure Health Products, LLC [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

3,096,827

TZ Wholesale LLC [Member]

Stock issued during period, shares, issued for services

2,000,000

Series A Preferred Stock [Member] | New Employment Agreement [Member] | Marco [Member]

Shares returned to the company

3

Consultant [Member]

Stock issued during period, shares, issued for services

2,000,000

250,000

250,000

250,000

500,000

250,000

2,000,000

250,000

250,000

250,000

250,000

250,000

250,000

125,000

250,000

250,000

250,000

150,000

250,000

150,000

250,000

5,418,301

15,511,767

Consultant [Member] | February 7, 2018 [Member]

Fair value of common stock charged to fees of related period

$ 9,825

Consultant [Member] | February 13, 2018 [Member]

Fair value of common stock charged to fees of related period

5,085

Consultant [Member] | February 14, 2018 [Member]

Fair value of common stock charged to fees of related period

8,500

Consultant [Member] | February 19, 2018 [Member]

Fair value of common stock charged to fees of related period

5,280

Consultant [Member] | February 26, 2018 [Member]

Fair value of common stock charged to fees of related period

11,375

Consultant [Member] | March 1, 2018 [Member]

Fair value of common stock charged to fees of related period

10,900

Consultant [Member] | March 20, 2018 [Member]

Fair value of common stock charged to fees of related period

6,500

Consultant [Member] | May 9, 2018 [Member]

Fair value of common stock charged to fees of related period

$ 1,812

Consultant [Member] | May 29, 2018 [Member]

Fair value of common stock charged to fees of related period

5,000

Consultant [Member] | May 31, 2018 [Member]

Fair value of common stock charged to fees of related period

4,600

Consultant [Member] | June 4, 2018 [Member]

Fair value of common stock charged to fees of related period

5,750

Consultant [Member] | June 18, 2018 [Member]

Fair value of common stock charged to fees of related period

6,250

Consultant [Member] | June 22, 2018 [Member]

Fair value of common stock charged to fees of related period

$ 8,250

Consultant [Member] | July 31, 2018 [Member]

Fair value of common stock charged to fees of related period

3,225

Consultant [Member] | August 28, 2018 [Member]

Fair value of common stock charged to fees of related period

159,600

Consultant [Member] | September 8, 2018 [Member]

Fair value of common stock charged to fees of related period

11,500

Consultant [Member] | September 10, 2018 [Member]

Fair value of common stock charged to fees of related period

19,950

Consultant [Member] | September 17, 2018 [Member]

Fair value of common stock charged to fees of related period

10,750

Consultant [Member] | September 18, 2018 [Member]

Fair value of common stock charged to fees of related period

13,725

Consultant [Member] | September 21, 2018 [Member]

Fair value of common stock charged to fees of related period

14,500

Consultant [Member] | September 25, 2018 [Member]

Fair value of common stock charged to fees of related period

97,400

Director One [Member]

Stock issued during period, shares, issued for services

3,000,000

Director One [Member] | February 9, 2018 [Member]

Fair value of common stock charged to fees of related period

101,400

Director Two [Member]

Stock issued during period, shares, issued for services

3,000,000

Director Two [Member] | February 9, 2018 [Member]

Fair value of common stock charged to fees of related period

$ 101,400

RedDiamond [Member]

Stock issued during the period

891,089

2,363,636

3,545,455

1,287,129

1,287,129

1,287,129

13,094,733

53,839,743

Dividend payable

$ 9,000

RedDiamond [Member] | Series B Preferred Stock [Member]

Stock retired during period, shares

10,000

15,000

10,000

10,000

10,000

101,736

263,263

Lender [Member]

Stock issued during period, shares, issued for services

2,749,429

Fair value of common stock charged to fees of related period

$ 15,000

Accrued interest payable

$ 10,221

$ 7,867

$ 7,266

$ 4,246

Common stock, shares issued in satisfaction of notes payable

9,372,100

8,430,331

9,544,292

Notes payable

$ 83,500

$ 38,500

$ 50,000

Consultant One [Member]

Stock issued during period, shares, issued for services

300,000

Consultant One [Member] | September 6, 2018 [Member]

Fair value of common stock charged to fees of related period

16,500

Consultant Two [Member]

Stock issued during period, shares, issued for services

500,000

Consultant Two [Member] | September 6, 2018 [Member]

Fair value of common stock charged to fees of related period

$ 27,500

Lender One [Member]

Accrued interest payable

$ 3,169

Common stock, shares issued in satisfaction of notes payable

5,121,694

Notes payable

$ 25,000

Lender Two [Member]

Accrued interest payable

$ 10,274

Common stock, shares issued in satisfaction of notes payable

10,045,667

Notes payable

$ 50,000

Investor [Member]

Stock issued during the period

7,407,407

Proceeds from issuance of common stock

$ 200,000

Common stock price per share

$ 0.027

Multiple Consultants [Member]

Stock issued during period, shares, issued for services

2,125,000

Fair value of common stock charged to fees of related period

$ 80,665

Three Board Members [Member]

Stock issued during period, shares, issued for services

1,500,000

Fair value of common stock charged to fees of related period

$ 62,342

Multiple Investors [Member]

Stock issued during the period

22,413,794

Proceeds from issuance of common stock

$ 650,000

Auctus, LLC [Member]

Common stock, shares issued for cashless exercise of stock options

891,089

Four Officers [Member]

Stock issued during period, shares, issued for services

4,370,629

Accrued compensation

$ 192,300

Hudilab, Inc. [Member] | License and Acquisition Agreement [Member]

Shares issued to acquire assets

7,500,000

Seven Chakras, LLC [Member] | Asset Purchase Agreement [Member]

Shares issued to acquire assets

1,000,000

Members of Advisory Board, Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

5,500,000

4,174,886

Subsequent Event [Member]

Stockholders' equity, reverse stock split

300:1 reverse split

300:1 reverse split

Stock Options and Warrants - P

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split (Details Narrative) - USD ($)	Oct. 15, 2019	Sep. 09, 2019	Oct. 21, 2018	Jun. 11, 2018	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Exercisable price per share
Stock options, fair value					$ 63,000	$ 192,000	$ 118,200	$ 84,000
Stock options, share price					$ 0.021	$ 0.024	$ 0.0395	$ 0.028
Stock options, expected term					3 years	3 years	5 years	5 years
Stock options, expected volatility rate					242.00%	242.00%	221.96%	262.00%
stock options, risk-free interest rate					1.60%	1.46%	3.05%	2.80%
Carl Dilley [Member]
Granted options				3,000,000
Stock issued in exchange for retirement of shares				3,000,000
Options exercisable for purchase of share				1
Exercisable price per share				$ 0.001
Expiration date				Jun. 11, 2023
Stanley L. Teeple [Member]
Granted options			3,000,000
Exercisable price per share			$ 0.001
Expiration date			Oct. 1, 2023
Johnny Mack [Member]
Granted options		8,000,000
Options exercisable for purchase of share		1
Exercisable price per share		$ 0.001
Expiration date		Sep. 9, 2022
Frederick Alger Boyer [Member]
Granted options	3,000,000
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.001
Jr., Ronald A. Silver [Member]
Granted options	3,000,000
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.001
James F. Murphy [Member]
Granted options	3,000,000
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.001

Stock Options and Warrants -_2

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split - Summary of Stock Options and Warrants Activity (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Beginning balance	8,297,500	297,500
Granted	17,000,000	8,850,000
Cancelled	(50,000)
Exercised		(850,000)
Ending balance	25,247,500	8,297,500
Warrant [Member]
Beginning balance	2,247,500	247,500
Granted		2,850,000
Cancelled
Exercised		(850,000)
Ending balance	2,247,500	2,247,500
Stock Option [Member]
Beginning balance	6,050,000	50,000
Granted	17,000,000	6,000,000
Cancelled	(50,000)
Exercised
Ending balance	23,000,000	6,050,000

Stock Options and Warrants -_3

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split - Schedule of Issued and Outstanding Stock Options (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Options Outstanding and Exercisable, Number | shares	23,000,000
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares
Stock Option 2018 [Member]
Number of Options Outstanding and Exercisable, Number | shares	6,000,000
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.001
Number of Options Outstanding and Exercisable, Expiration year	2023
Stock Option 2019 [Member]
Number of Options Outstanding and Exercisable, Number | shares	17,000,000
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.001
Number of Options Outstanding and Exercisable, Expiration year	2022

Stock Options and Warrants -_4

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split - Schedule of Issued and Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	2,247,500
2010 Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	247,500
Number of Warrants Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 1
Number of Warrants Outstanding and Exercisable, Expiration year	2020
2018 Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	2,000,000
Number of Warrants Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.04345	[1]
Number of Warrants Outstanding and Exercisable, Expiration year	2023
[1]	110% of the closing price of the Company's common stock on the date that the Holder funds the full purchase price of the Note.

Stock Options and Warrants -_5

Stock Options and Warrants - Prior to 300:1 Reverse Stock Split - Schedule of Issued and Outstanding Warrants (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2019
2018 Warrant [Member]
Percentage of closing price of common stock funding purchase price	110.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 2,084
Federal income tax rate	21.00%
Deferred income tax asset, valuation allowance	$ 1,300,168	984,478
Operating loss carryforwards	$ 6,191,273
Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent	100.00%
Operating loss carryforwards, 2025	$ 1,369
Operating loss carryforwards, 2026	518,390
Operating loss carryforwards, 2027	594,905
Operating loss carryforwards, 2028	686,775
Operating loss carryforwards, 2029	159,141
Operating loss carryforwards, 2030	151,874
Operating loss carryforwards, 2031	135,096
Operating loss carryforwards, 2032	166,911
Operating loss carryforwards, 2033	311,890
Operating loss carryforwards, 2034	25,511
Operating loss carryforwards, 2035	338,345
Operating loss carryforwards, 2036	381,638
Operating loss carryforwards, 2037	499,288
Operating loss carryforwards, 2038	716,858
Operating loss carryforwards, 2039	1,503,282
Income tax examination, penalties and interest expense

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provisions for (Benefits from) Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Expected income tax (benefit) at 21%	$ (964,419)	$ (863,578)
Non-deductible stock-based compensation	648,729	583,653
Non-deductible amortization of debt discounts		37,064
Loss on stock issuance		136,344
Loss on debt conversion		272,867
Non-deductible expense from derivative liability		(334,139)
Loan forgiveness		18,024
Increase in deferred income tax assets valuation allowance	315,690	149,765
Provision for (benefit from) income taxes	$ 2,084

Income Taxes - Schedule of Pr_2

Income Taxes - Schedule of Provisions for (Benefits from) Income Taxes (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal income tax rate	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 1,300,168	$ 984,478
Valuation Allowance	(1,300,168)	(984,478)
Net

Segment Information (Details Na

Segment Information (Details Narrative)	12 Months Ended
	Dec. 31, 2019Integer
Segment Reporting [Abstract]
Number of reportable segments	1

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenue from external customers		$ 2,305,503	$ 668,603
Segment assets	$ 6,930,870	6,930,870	3,693,675
Income before income taxes		(4,590,386)	$ (4,112,277)
Durable Equipment Products [Member]
Revenue from external customers	466,920	1,436,403
Revenue from other segments
Segment profit	309,370	809,631
Segment assets	1,994,845	1,994,845
Total profit for reportable segment	309,208	810,060
Other income (expense) - net	162	(429)
Income before income taxes	$ 309,370	$ 809,631

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

Oct. 10, 2019

Oct. 04, 2019

Sep. 06, 2019

May 01, 2019

Apr. 02, 2019

Dec. 29, 2018

Dec. 28, 2018

Nov. 12, 2018

Oct. 21, 2018

Oct. 15, 2018

Feb. 16, 2018

Feb. 12, 2018

Nov. 09, 2017

Oct. 03, 2017

Sep. 06, 2017

Dec. 01, 2014

May 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Oct. 31, 2019

Jan. 02, 2019

Aug. 06, 2018

Sep. 11, 2015

Employee cash compensation per month

$ 2,263,566

$ 1,478,987

Exercisable price per share

Professional fees

$ 287,441

117,718

Rent expense

246,968

67,165

Monthly rentals for lease year 1

45,913

Monthly rentals for lease year 2

47,055

Monthly rentals for lease year 3

15,685

Operating lease, right-of-use asset

96,980

$ 100,681

Lease liability

$ 97,279

$ 90,591

Estimated incremental borrowing rate

10.00%

Future lease payments

$ 108,653

Sales Revenue, Net [Member] | No Customer [Member]

Concentration risk percentage

10.00%

Sales Revenue, Net [Member] | One Customer [Member]

Concentration risk percentage

16.00%

Stanley L. Teeple [Member]

Granted options to purchase stock

3,000,000

Exercisable price per share

$ 0.001

Executive Employment Agreement [Member] | Marco [Member]

Employee cash compensation per month

$ 10,000

New Employment Agreement [Member] | Marco [Member]

Employee cash compensation per month

$ 15,000

New Employment Agreement [Member] | Marco [Member] | Common Stock [Member]

Number of shares issued as a result of conversion

30,000,000

Stock issued during period, shares, issued for services

30,000,000

New Employment Agreement [Member] | Andrew W Holtmeyer [Member]

Employee cash compensation per month

$ 15,000

Employment term

4 years

New Employment Agreement [Member] | Andrew W Holtmeyer [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

245,789

Executive Service Agreement [Member] | David Posel [Member]

Employee cash compensation per month

$ 5,000

Employment term

4 years

Executive Service Agreement [Member] | David Posel [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

1

Executive Service Agreement [Member] | Andrew W Holtmeyer [Member]

Employee cash compensation per month

$ 10,000

Employment term

3 years

Executive Service Agreement [Member] | Andrew W Holtmeyer [Member] | Series A Preferred Stock [Member]

Issuance of shares, description

3, 2 and 1 share of Series A Preferred Stock at the beginning of each year

Employment Agreement [Member] | Stanley L. Teeple [Member]

Employee cash compensation per month

$ 15,000

Employment term

4 years

Employment Agreement [Member] | Stanley L. Teeple [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

1

3

Employment Agreement [Member] | Pasquale Ferro [Member]

Employee cash compensation per month

$ 15,000

Vesting term

4 years

Employment Agreement [Member] | Pasquale Ferro [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

5

New Employment Services Agreement [Member] | Johnny J. Mack [Member]

Employee cash compensation per month

$ 15,000

Granted options to purchase stock

32,000,000

Number of stock options vesting

8,000,000

Exercisable price per share

$ 0.001

Accrued employee benefits

$ 13,315

Retention of options

8,000,000

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | First Anniversary [Member]

Number of stock options vesting

8,000,000

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | Second Anniversary [Member]

Number of stock options vesting

8,000,000

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | Third Anniversary [Member]

Number of stock options vesting

8,000,000

Employee Agreement [Member] | Philip Scala [Member]

Employee cash compensation per month

$ 2,500

Employment term

3 years

Granted options to purchase stock

500,000

Shares issued price per share

$ 0.001

Consulting Agreement [Member] | T8 Partners LLC [Member] | Restricted Stock [Member]

Stock issued during period, shares, issued for services

10,000,000

Consulting Agreement [Member] | Healthcare Advisory Group [Member] | Restricted Stock [Member]

Stock issued during period, shares, issued for services

5,000,000

Consulting Agreement [Member] | Common Stock [Member] | T8 Partners LLC [Member] | Restricted Stock [Member]

Stock issued during period, shares, issued for services

2,500,000

Consulting Agreement [Member] | Common Stock [Member] | Healthcare Advisory Group [Member] | Restricted Stock [Member]

Stock issued during period, shares, issued for services

2,500,000

Investor Relations and Advisory Agreement [Member] | Restricted Stock [Member]

Professional fees

$ 5,500

Decrease in fee amount

$ 4,000

Lease Agreement [Member] | KLAM, Inc [Member]

Initial term of lease

1 year

Rent expense

$ 2,500

Lease Agreement [Member] | Unrelated Third Party [Member]

Initial term of lease

37 months

Monthly rentals for lease year 1

$ 2,922

Monthly rentals for lease year 2

3,009

Monthly rentals for lease year 3

$ 3,100

Renewed Lease Agreement [Member] | Unrelated Third Party [Member]

Monthly rentals for lease year 1

$ 3,807

$ 3,193

Monthly rentals for lease year 2

$ 3,921

3,289

Monthly rentals for lease year 3

$ 3,388

Renewal term of lease

30 months

36 months

Operating lease, right-of-use asset

$ 100,681

Lease liability

90,591

Adjusted modification of lease liabilities

$ 103,260

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Year ended December 31, 2020	$ 45,913
Year ended December 31, 2021	47,055
Year ended December 31, 2022	15,685
Total	$ 108,653

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	12 Months Ended
	Dec. 31, 2019USD ($)
Products sales to related parties	$ 0
LI Accounting Associates, LLC [Member]
Related party expense	$ 10,750

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 03, 2020
Iconic Brands, Inc. [Member]
Equity interest, description	The Company acquired 51% of Green Grow Farms, Inc. (GGFI) in December 2019 for 37.5 million shares of CANB common stock. The remaining 49% of GGFI was held by New York Farm Group (NYFG). Post-closing of the original agreement, the Company discovered certain assets needed reassessment and reconsideration. In settlement of certain claims held by the Company as a result of the foregoing, NYFG agreed to assign the Company its 49% interest in GGFI and 1,000,000 shares of Iconic Brands, Inc (ICNB) stock in consideration for a release from the Company. The settlement agreement was executed on March 3, 2020.
Number of shares issued for acquisition	37,500,000
Iconic Brands, Inc. [Member] | Subsequent Event [Member]
Ownership percentage		51.00%
Number of shares issued for acquisition, value		$ 1,000,000
New York Farm Group [Member] | Subsequent Event [Member]
Ownership percentage		49.00%
Number of shares issued for acquisition, value		$ 1,000,000